跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 181 条关于
“CLN1”
全部
181
临床试验
111
药物
54
机构
0
资讯
16
去年
NCL Translational Research Conference Highlights Advances in Batten Disease Therapies
去年
FDA Grants Fast Track Designation to Alentis Therapeutics' ALE.P02 for CLDN1+ Squamous Cancers
2年前
FDA Expands Brineura Approval to Include All Ages with CLN2 Disease
去年
ALE.P02 Receives FDA Fast Track Designation for CLDN1-Positive Solid Tumors
去年
FDA Grants Fast Track Designation to Alentis Therapeutics' ALE.P02 for CLDN1+ Squamous Solid Tumors
去年
FDA Grants Fast Track Designation to Alentis Therapeutics' ALE.P02 for CLDN1-Positive Solid Tumors
去年
Alentis' CLDN1-Targeting ADC, ALE.P02, Receives FDA Fast Track for Advanced Squamous Cancers
去年
Novel Nanoparticle Therapy Agg-CLNP Shows Promise for Preventing Rheumatoid Arthritis and Reducing Flares
去年
NICE Extends Access to Brineura for CLN2 Batten Disease While Seeking Long-term Solution
上个月
New Retina Model Reveals How CLN3-Batten Disease Damages Vision and Points to a Treatment
第 1 页,共 2 页
上一页
下一页